Home > Insider Trading > Filing (0000899243-16-033198)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1559053	Prothena Corp Plc	PRTA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1232119	W Arthur Homan	C/O Prothena Biosciences Inc 650 Gateway Boulevard South San Francisco CA 94080	Chief Legal Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares, Par Value $0.01 Per Share	Acquisiton	2016-11-09	3,125	$22.14	3,125	No	4	M	Direct
Ordinary Shares, Par Value $0.01 Per Share	Disposition	2016-11-09	3,125	$52.19	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Option (right to buy)	Disposition	2016-11-09	3,125	$0.00	3,125	$22.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
75,000		2024-05-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Ordinary Shares, Par Value $0.01 Per Share	2,000	Indirect	By Trust

Footnotes

The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from $52.15 to $52.47, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The shares are held by the Homan Family Trust, dated 9/21/2001, of which the Reporting Person is a trustee.
The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 30, 2015 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.